(XNCR) Xencor - Ratings and Ratios
Engineered Monoclonal Antibodies, Bispecific Antibodies, Antibody Drug Candidates, Clinical-Stage Therapeutics
| Risk via 10d forecast | |
|---|---|
| Volatility | 59.8% |
| Value at Risk 5%th | 91.0% |
| Reward | |
|---|---|
| Sharpe Ratio | -0.48 |
| Alpha | -55.88 |
| Character | |
|---|---|
| Hurst Exponent | 0.520 |
| Beta | 0.981 |
| Drawdowns 3y | |
|---|---|
| Max DD | 81.06% |
| Mean DD | 44.77% |
Description: XNCR Xencor October 23, 2025
Xencor Inc. (NASDAQ: XNCR) is a clinical-stage biopharma that engineers monoclonal antibodies using its XmAb™ platform. Its marketed assets include Ultomiris (atypical hemolytic uremic syndrome, generalized myasthenia gravis, neuromyelitis optica spectrum disorder), Monjuvi (relapsed/refractory diffuse large B-cell lymphoma) and the antiviral Sotrovimab. The pipeline spans multiple bispecific antibodies-XmAb819 (renal cell carcinoma), XmAb541 (ovarian cancer), Vudalimab (metastatic castration-resistant prostate cancer), XmAb564 (autoimmune disease), and Plamotamab (lymphoma)-as well as T-cell engagers, Fc-engineered candidates, and viral therapeutics.
Key quantitative signals (as of the most recent 10-Q) show Xencor’s cash runway of roughly $300 million, a quarterly burn of $55 million, and a revenue base of $140 million driven primarily by Ultomiris royalties and Monjuvi sales. The company’s R&D intensity-≈ 38 % of total expenses-reflects its heavy reliance on advancing early-stage bispecifics. Sector-wide, the global antibody therapeutics market is projected to grow > 10 % CAGR through 2030, powered by demand for targeted oncology and immunology treatments, while U.S. biotech funding remains robust (≈ $30 billion in Q2 2024 venture capital). Xencor’s focus on engineered bispecifics aligns with the observed premium pricing of novel antibody formats, but execution risk remains high given the early-phase status of most candidates.
If you want a data-rich, model-backed view of Xencor’s valuation assumptions and scenario analysis, the ValueRay platform provides a useful starting point for deeper research.
XNCR Stock Overview
| Market Cap in USD | 993m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 2013-12-03 |
| Return 12m vs S&P 500 | -48.8% |
| Analyst Rating | 4.50 of 5 |
XNCR Dividends
Currently no dividends paidXNCR Growth Ratios
| CAGR | -22.70% |
| CAGR/Max DD Calmar Ratio | -0.28 |
| CAGR/Mean DD Pain Ratio | -0.51 |
| Current Volume | 959.3k |
| Average Volume | 1219.5k |
Piotroski VR‑10 (Strict, 0-10) 0.0
| Net Income (-138.7m TTM) > 0 and > 6% of Revenue (6% = 8.78m TTM) |
| FCFTA -0.17 (>2.0%) and ΔFCFTA -2.68pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 295.1% (prev 473.2%; Δ -178.1pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.16 (>3.0%) and CFO -139.0m <= Net Income -138.7m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 5.99 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (74.4m) change vs 12m ago 16.23% (target <= -2.0% for YES) |
| Gross Margin 61.46% (prev 87.87%; Δ -26.40pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 15.80% (prev 10.34%; Δ 5.46pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -1.39 (EBITDA TTM -72.8m / Interest Expense TTM 58.5m) >= 6 (WARN >= 3) |
Altman Z'' -3.68
| (A) 0.50 = (Total Current Assets 518.4m - Total Current Liabilities 86.5m) / Total Assets 868.8m |
| (B) -0.91 = Retained Earnings (Balance) -789.3m / Total Assets 868.8m |
| (C) -0.09 = EBIT TTM -81.1m / Avg Total Assets 926.2m |
| (D) -3.23 = Book Value of Equity -787.4m / Total Liabilities 243.5m |
| Total Rating: -3.68 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 19.29
| 1. Piotroski 0.0pt = -5.0 |
| 2. FCF Yield -19.85% = -5.0 |
| 3. FCF Margin -98.17% = -7.50 |
| 4. Debt/Equity 0.32 = 2.45 |
| 5. Debt/Ebitda -2.39 = -2.50 |
| 6. ROIC - WACC (= -20.31)% = -12.50 |
| 7. RoE -21.65% = -2.50 |
| 8. Rev. Trend 18.93% = 1.42 |
| 9. EPS Trend 8.45% = 0.42 |
What is the price of XNCR shares?
Over the past week, the price has changed by -1.43%, over one month by +5.45%, over three months by +96.29% and over the past year by -41.06%.
Is Xencor a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of XNCR is around 11.26 USD . This means that XNCR is currently overvalued and has a potential downside of -18.05%.
Is XNCR a buy, sell or hold?
- Strong Buy: 8
- Buy: 3
- Hold: 0
- Sell: 1
- Strong Sell: 0
What are the forecasts/targets for the XNCR price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 27.7 | 101.8% |
| Analysts Target Price | 27.7 | 101.8% |
| ValueRay Target Price | 12.6 | -8.6% |
XNCR Fundamental Data Overview November 11, 2025
P/S = 6.6116
P/B = 1.359
Beta = 0.981
Revenue TTM = 146.4m USD
EBIT TTM = -81.1m USD
EBITDA TTM = -72.8m USD
Long Term Debt = 115.2m USD (from longTermDebt, last fiscal year)
Short Term Debt = 49.3m USD (from shortTermDebt, last quarter)
Debt = 202.4m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 174.1m USD (from netDebt column, last quarter)
Enterprise Value = 724.0m USD (992.6m + Debt 202.4m - CCE 471.0m)
Interest Coverage Ratio = -1.39 (Ebit TTM -81.1m / Interest Expense TTM 58.5m)
FCF Yield = -19.85% (FCF TTM -143.7m / Enterprise Value 724.0m)
FCF Margin = -98.17% (FCF TTM -143.7m / Revenue TTM 146.4m)
Net Margin = -94.80% (Net Income TTM -138.7m / Revenue TTM 146.4m)
Gross Margin = 61.46% ((Revenue TTM 146.4m - Cost of Revenue TTM 56.4m) / Revenue TTM)
Gross Margin QoQ = none% (prev 93.92%)
Tobins Q-Ratio = 0.83 (Enterprise Value 724.0m / Total Assets 868.8m)
Interest Expense / Debt = 3.79% (Interest Expense 7.67m / Debt 202.4m)
Taxrate = -0.69% (negative due to tax credits) (1.62m / -234.9m)
NOPAT = -81.7m (EBIT -81.1m * (1 - -0.69%)) [loss with tax shield] [negative tax rate / tax credits]
Current Ratio = 5.99 (Total Current Assets 518.4m / Total Current Liabilities 86.5m)
Debt / Equity = 0.32 (Debt 202.4m / totalStockholderEquity, last quarter 625.3m)
Debt / EBITDA = -2.39 (negative EBITDA) (Net Debt 174.1m / EBITDA -72.8m)
Debt / FCF = -1.21 (negative FCF - burning cash) (Net Debt 174.1m / FCF TTM -143.7m)
Total Stockholder Equity = 640.8m (last 4 quarters mean from totalStockholderEquity)
RoA = -15.97% (Net Income -138.7m / Total Assets 868.8m)
RoE = -21.65% (Net Income TTM -138.7m / Total Stockholder Equity 640.8m)
RoCE = -10.73% (EBIT -81.1m / Capital Employed (Equity 640.8m + L.T.Debt 115.2m))
RoIC = -11.66% (negative operating profit) (NOPAT -81.7m / Invested Capital 700.5m)
WACC = 8.64% (E(992.6m)/V(1.20b) * Re(9.63%) + D(202.4m)/V(1.20b) * Rd(3.79%) * (1-Tc(-0.01)))
Discount Rate = 9.63% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 10.59%
Fair Price DCF = unknown (Cash Flow -143.7m)
EPS Correlation: 8.45 | EPS CAGR: 4.37% | SUE: 2.33 | # QB: 2
Revenue Correlation: 18.93 | Revenue CAGR: 32.42% | SUE: 0.90 | # QB: 1
Additional Sources for XNCR Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle